DIA EUROPE 2020

This session will explore and anticipate what the systematic and meaningful patient engagement in medicines R&D will change in the development of new therapies for each stakeholders. Indeed, patient engagement, even though at the top of the agenda, is not yet fully implemented. The discussions will look at the day after tomorrow, when patient engagement will not be an advocacy topic anymore and has become the norm. The topics covered will (not exhaustively) be the putative nature changes of the medical expertise, its specificity of data gathering and by whom, the auditability and the subsequent trust in the data captured by patients themselves or patient organisations, the possible ‘Institutionalisation’ and independence of the patient organisations, the challenges due to the scale up of the current capacities in all stakeholders, new routes of patient organisations funding, the differential roles of online communities, patient experts and patient organisations, and many more (that needs to be discussed with each of the speakers).